Condition: Moderate to Severe Persistent Asthma · Sponsor: Connect Biopharm LLC
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Connect Investigative Site 154 | Tucson, Arizona, United States | — |
| Connect Investigative Site 109 | Huntington Beach, California, United States | — |
| Connect Investigative Site 143 | Huntington Beach, California, United States | — |
| Connect Investigative Site 132 | Lancaster, California, United States | — |
| Connect Investigative Site 125 | Mission Viejo, California, United States | — |
| Connect Investigative Site 103 | San Jose, California, United States | — |
| Connect Investigative Site 161 | Hialeah, Florida, United States | — |
| Connect Investigative Site 114 | Hollywood, Florida, United States | — |
| Connect Investigative Site 142 | Leesburg, Florida, United States | — |
| Connect Investigative Site 104 | Miami, Florida, United States | — |
| Connect Investigative Site 166 | Miami, Florida, United States | — |
| Connect Investigative Site 118 | Miami, Florida, United States | — |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04773678